Davunetide: Research & Studies

Research Overview#

Davunetide has a moderate evidence base including a well-conducted phase 2/3 randomized controlled trial in PSP that failed to show efficacy. Extensive preclinical data supports the microtubule stabilization mechanism, but clinical translation has been challenging.

PSP Phase 2/3 Trial (Boxer et al., 2014)#

The pivotal trial (PMID: 24873720) enrolled 313 participants across 48 centers in six countries. Key details:

• Randomized 1:1 to davunetide 30 mg BID intranasally or placebo for 52 weeks
• Primary endpoints: change in PSP Rating Scale and Schwab and England Activities of Daily Living scale
• Results: No significant difference between groups on either primary endpoint
• Completion rate: 77% (241 of 313 completed)
• Safety: Davunetide was well tolerated with adverse event rates comparable to placebo

The negative result led to the insolvency of Allon Therapeutics. The failure may reflect limitations of the PSP indication rather than davunetide's mechanism, as PSP is a rapidly progressing and heterogeneous tauopathy.

Preclinical Evidence#

Extensive preclinical studies demonstrate that davunetide:

• Stabilizes microtubules by interacting with tubulin
• Reduces tau hyperphosphorylation in transgenic mouse models
• Decreases alpha-synuclein inclusions and improves motor function in synucleinopathy models
• Provides neuroprotection against oxidative stress, glucose deprivation, and excitotoxicity
• Crosses the blood-brain barrier via intranasal delivery

ADNP Syndrome Development#

ExoNavis licensed davunetide in 2021 and initiated a phase 3 trial in 2024 testing davunetide in 97 children with ADNP mutations (Helsmoortel-Van der Aa syndrome). This represents a precision medicine approach, targeting the genetic condition most directly related to davunetide's mechanism (ADNP deficiency).

Research Evidence Context#

Davunetide belongs to the Neuroprotective category of research peptides. The research evidence for Davunetide spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Davunetide:

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial#

Authors: Boxer AL, Lang AE, Grossman M, et al. (2014) — Lancet Neurology

Phase 2/3 randomized trial of intranasal davunetide (30 mg BID) in 313 PSP patients over 52 weeks. Failed to demonstrate efficacy on primary endpoints.

Key Findings:

• 313 patients randomized 1:1 to davunetide or placebo
• No significant difference in PSP Rating Scale change from baseline
• No significant difference in Schwab and England ADL scale
• 77% completion rate (241 of 313 completed the study)
• Davunetide was well tolerated with comparable adverse event rates

Limitations: Failed efficacy trial; PSP may not be the optimal indication for microtubule stabilization; single dose tested; disease heterogeneity

Evidence Quality Assessment#

The overall evidence level for Davunetide is classified as moderate. There is meaningful clinical evidence from Phase 2 or similar trials, though larger confirmatory studies may be needed.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Davunetide have been identified:

• Efficacy in ADNP syndrome (phase 3 trial initiated 2024)
• Whether microtubule stabilization is beneficial in other tauopathies (AD, FTD)
• Optimal patient selection biomarkers for davunetide response
• Combination therapy approaches with other neuroprotective agents

Addressing these research gaps will be important for establishing a more complete understanding of Davunetide's therapeutic potential and safety profile.

Related Reading#

• Davunetide overview and research guide
• Davunetide dosing protocols
• Davunetide molecular structure